Case Study: Corcept Therapeutics
A case study on Quotient Sciences' accelerated approach to integrated clinical manufacturing and Phase 1 clinical trials
Corcept Therapeutics, based in California, USA, is a pharmaceutical company focused on the impact of cortisol on health and the development of glucocorticoid receptor (GR) antagonists. Following its foundation in 1998, the company successfully developed Korlym® (mifepristone), a dual GR and progesterone receptor (PR) antagonist for the treatment of endogenous Cushing’s syndrome (Hypercortisolism), a disorder associated with significant morbidity and mortality. However, the dual action of mifepristone limited the circumstances in which the drug could be used, and there was a need for a selective 'next generation' medication offering all of the benefits but without the associated risks.
Quotient Sciences was approached to help Corcept Therapeutics in their development of CORT125134. This was contracted out to us due to our ability to integrate clinical manufacturing and clinical trial dosing at the same location. Request a copy of our case study today and contact us to find out how we can accelerate drug development timelines saving as much as 12 months in the process with our Translational Pharmaceutics® platform.